 DiaMedica Therapeutics Inc. Nasdaq: DMAC, a clinical-stage biotechnology company, announced today the pricing of the previously announced underwritten registered public offering of 4,000,000 of its common shares at a price to the public of 5.00 per share. DiaMedica has also granted the underwriters a 30-day option to purchase up to an additional 600,000 common shares, at the public offering price, less underwriting discounts and commissions. All of the common shares are being offered by DiaMedica. The offering is expected to close on or about August 10, 2020, subject to the satisfaction of customary closing conditions. 